成中的神经标志物:定义,发展策略和最近的进展
Nicholas R Harp1, Tor D Wager2, Hedy Kober3
1Department of Psychiatry, Yale University, New Haven, CT, USA.
Journal of neural transmission (Vienna, Austria : 1996)
|April 17, 2024
概括
开发基于大脑的神经标志物对于理解物质使用障碍 (SUDs) 至关重要. 神经生物学渴望签名 (NCS) 显示出诊断,预测和监测SUD和治疗反应的前景.
科学领域:
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
- 生物标志物开发 生物标志物开发
背景情况:
- 药物使用障碍 (SUDs) 由于其高患病率和成本,构成了重大的公共卫生挑战.
- 迫切需要可靠的生物标志物,特别是基于大脑的神经标志物,以推进对SUD神经生物学的理解并改善临床实践.
- 神经标志物对于索引SUD的易感性,诊断,预后,监测和治疗反应至关重要.
研究的目的:
- 为SUDs开发和评估强大的神经标志物的指导方针概述.
- 审查最近成神经科学的进展,重点关注神经标志物.
- 突出神经生物学渴望特征 (NCS) 的潜力,作为SUD的有前途的神经标志物.
主要方法:
- 关于神经标志物开发和在成神经科学中的应用现有文献的综述.
- 专注于验证神经标志物的标准:灵敏度,特异性,预测建模和通用性.
- 在渴望的背景下对神经生物学渴望特征 (NCS) 的具体检查,这是SUD的核心特征.
主要成果:
- 建立了开发和评估神经标志物的标准,强调敏感性,特异性,预测有效性和可概括性.
- 确定渴望是SUD中神经标志物发展的关键目标.
- 神经生物学渴望特征 (NCS) 显示出作为可靠的神经标志物的巨大潜力.
结论:
- 强大的神经标志物对于推进SUD研究和临床应用至关重要.
- 对于解决SUD诊断,预后和治疗监测中客观措施的需求,NCS具有相当大的希望.
- 对像NCS这样的神经标志物的进一步研究和验证对于改善药物使用障碍患者的治疗结果至关重要.
更多相关视频
相关概念视频
Drug Abuse and Addiction: Pharmacological Phenomena
469
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
469
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
188
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
188
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
122
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
122
Drugs Affecting Neurotransmitter Release or Uptake
1.0K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.0K
Substance Use Disorders Affecting Sleep
166
Substance use disorders involve a pattern of using drugs more extensively than intended and continuing use despite harmful consequences. This includes legal substances like alcohol and nicotine, as well as illegal drugs. These disorders often involve both physical and psychological dependence, reflecting compulsive use of substances that significantly alter thoughts, feelings, and behaviors, contributing to a major public health issue.
Understanding the concepts of physical dependence,...
Understanding the concepts of physical dependence,...
166
Alzheimer's Disease: Overview
468
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
468


